GENE ONLINE|News &
Opinion
Blog

BeiGene
Putting Patients First: The Quest to Make Anticancer Cell Therapy Accessible to All
2023-07-04
Cell Therapy as a Pillar of Future Therapeutics, an Interview with Alex Huang, Vice President and Head of Cell Therapy at BeiGene
2022-10-05
BeiGene Granted NMPA Approval to Treat World’s Most Prevalent Esophageal Cancer
2022-04-20
EMA Begins Review of BeiGene, Novartis’s PD-1 Antibody for Esophageal and Lung Cancer
2022-04-13
Biotech Showcase 2022: The China Factor
2022-01-24
Novartis Licenses BeiGene’s Antibody for a Potential $2.8 Billion After Its Own Drug Disappoints
2021-12-21
BeiGene launches IPO on Shanghai’s STAR market to raise $3B
2021-12-03
Brukinsa Receives EU Approval for the Treatment of Rare Lymphoma
2021-11-27
San Diego Startup Nabs $140 Million Following BeiGene, Kite Partnerships
2021-11-03
BeiGene Gets Its First Regulatory Nod in Australia for Rare Lymphoma
2021-10-08
FDA Accepts BeiGene’s BLA for Esophageal Cancer Drug
2021-09-14
BeiGene’s Brukinsa Bags Second FDA Approval, to Rival Imbruvica in Treating a Rare Cancer
2021-09-06
Chinese Regulator Accepts BeiGene’s Tislelizumab sBLA for Nasopharyngeal Cancer
2021-08-23
China’s BeiGene to Build a Biologics Manufacturing Site in the US
2021-08-04
BITT’s TNFR2 Antagonist to Enter Clinical Trials In Collaboration with BeiGene
2021-02-20
1 2
LATEST
Ginkgo Bioworks and Pfizer Forge $331 Million Collaboration for RNA-Based Drug Discovery
2023-09-29
Johnson & Johnson Partners with Singapore to Boost Life Sciences Innovation
2023-09-28
Vietnam and South Korea Strengthen Cooperation in Multiple Sectors
2023-09-27
PeptiDream and Genentech Collaborate on Novel Peptide-Radioisotope Drug Conjugates
2023-09-27
AcuraStem and Takeda Collaborate on Innovative ALS Treatment
2023-09-27
Seven AI/ML for Life Sciences Companies Identified as Innovators in New Clarivate Companies to Watch Report
2023-09-27
GeneOnline’s Weekly News Highlights: Sept 17-Sept 22
2023-09-26
EVENT
2023-10-04
BioFuture 2023
New York city,USA
Scroll to Top